Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Current perspectives on the use of eplerenone for chronic central serous chorioretinopathy

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Choroidal neovascularization in a 47-year-old male patient with central serous chorioretinopathy.


  1. Lotery A, Sivaprasad S, O’Connell A, Harris RA, Culliford L, Ellis L, et al. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomized, double-blind, placebo-controlled trial. Lancet. 2020;395:294–303.

    CAS  Article  Google Scholar 

  2. Petkovsek DS, Cherfan DG, Conti FF, Hom GL, Ehlers JP, Babiuch AS, et al. Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience. Br J Ophthalmol. 2020;104:182–7.

    Article  Google Scholar 

  3. Fraenkel D, Suffo S, Langenbucher A, Seitz B, Din Abdin A. Eplerenone for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol. 2020; 1120672120952648. Online ahead of print.

  4. Haimovici R, Rumelt S, Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology. 2003;110:698–703.

    Article  Google Scholar 

  5. Zhao M, Célérier I, Bousquet E, Jeanny JC, Jonet L, Savoldelli M, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Investig. 2012;122:2672–9.

    CAS  Article  Google Scholar 

  6. Van Rijssen TJ, van Dijk EHC, Yzer S, Ohno-Matsui K, Keunen JEE, Schlingemann RO, et al. Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res. 2019;73:100770.

    Article  Google Scholar 

  7. Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB. Pachychoroid disease. Eye. 2019;33:14–33.

    Article  Google Scholar 

  8. Min JY, Lv Y, Yu S, Gong YY. Findings of OCT-angiography compared to fluorescein and indocyanine green angiography in central serous chorioretinopathy. Lasers Surg Med. 2018;50:987–93.

    Article  Google Scholar 

  9. Sulzbacher F, Schütze C, Burgmüller M, Vécsei-Marlovits PV, Weingessel B. Clinical evaluation of neovascular and non-neovascular chronic central serous chorioretinopathy (CSC) diagnosed by swept source optical coherence tomography angiography (SS OCTA). Graefes Arch Clin Exp Ophthalmol. 2019;257:1581–90.

    Article  Google Scholar 

  10. Sadda SR. Lack of efficacy of eplerenone for treatment of active central serous chorioretinopathy. Eye. 2020;34:1489–90.

    Article  Google Scholar 

  11. Hua R, Liu L, Li C, Chen L. Evaluation of the effects of photodynamic therapy on chronic central serous chorioretinopathy based on the mean choroidal thickness and the lumen area of abnormal choroidal vessels. Photodiagnosis Photodyn Ther. 2014;11:519–25.

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Rui Hua.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Xia, Y., Hua, R. Current perspectives on the use of eplerenone for chronic central serous chorioretinopathy. Eye 35, 3445–3447 (2021).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

Further reading


Quick links